Conditional neuromodulation of neurogenic detrusor overactivity using transrectal stimulation in patients with spinal cord injury: A proof of principle study by Knight, SL et al.
Received: 5 December 2016 | Accepted: 30 March 2017
DOI: 10.1002/nau.23310
ORIGINAL CLINICAL ARTICLE
Conditional neuromodulation of neurogenic detrusor
overactivity using transrectal stimulation in patients with spinal
cord injury: A proof of principle study
Sarah Louise Knight1,2 | Nuwani Edirisinghe3 | Brian Leaker4 | Judith Susser1 |
Michael Duncan Craggs1,2
1 London Spinal Cord Injury Centre, Royal
National Orthopaedic Hospital, Stanmore,
UK
2Division of Surgery and Interventional
Science, University College London,
London, UK
3Department of Medical Physics
Bioengineering, University College London,
London, UK
4Nephro-Urology Clinical Trials Ltd.,
Queen Anne Street Medical Centre,
London, UK
Correspondence
Dr Sarah Louise Knight, London Spinal
Cord Injury Centre, Royal National
Orthopaedic Hospital, Stanmore HA7 4LP,
UK.
Email: sarah.knight@rnoh.nhs.uk
Funding information
Engineering and Physical Sciences
Research Council Dorothy Hodgkin Award;
Nephro-Urology Clinical Trials Limited
Aims: A proof of principle study of a novel wearable device to control neurogenic
detrusor over-activity in eight male spinal cord injured subjects using conditional
neuromodulation.
Methods: Transrectal stimulation was delivered through the device in response to
simultaneously recorded external anal sphincter (EAS) contraction as a marker for
neurogenic detrusor overactivity (NDO). The effect of conditional neuromodulation
on bladder capacity and maximum detrusor pressure was investigated in addition to
reliability of dyssynergic sphincter contraction as a marker for NDO.
Results: Conditional neuromodulation through the novel device showed a
statistically significant increase in bladder capacity and reduction in maximum
detrusor pressure in six male subjects with spinal cord injury (SCI). EAS activity was
a reliable surrogate for detection of NDO.
Conclusions: It has been shown for the first time that conditional neuromodulation
can be delivered and triggered via a single biocompatible device placed in the anal
canal. The pudendal nerves lying in Alcock's canal were stimulated through the wall
of the anal canal, and the dyssynergic activity of the EASwas used to detect NDO and
trigger neuromodulation giving significant increases in bladder capacity and
reduction in detrusor pressure in six male subjects with SCI.
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1 | INTRODUCTION
Following a supra-sacral spinal cord injury (SCI), there are
profound alterations in bladder function which usually result
in incontinence secondary to neurogenic detrusor overactivity
(NDO) and associated detrusor sphincter dyssynergia
(DSD).1 If left uncontrolled, these uninhibited reflexes may
lead to impaired renal function as a result of reflux,
incomplete emptying, and recurrent infection.
The ultimate goal in the urological management of
patients with NDO and DSD is to increase bladder capacity
and reduce bladder pressures, in order to protect the upper
tracts and minimize incontinence. At present, this can be
achieved using pharmacological methods, surgical proce-
dures, or with the use of implanted electrical stimulation
devices in combination with catheterization of the bladder.
A recent systematic review has shown that transcutaneous
electrical stimulation is a safe and effective treatment for the
neurogenic bladder, but the quality of evidence is low and
many studies only have small numbers.2 Electrical stimula-
tion (also known as neuromodulation) of the sacral, pudendal,
and tibial nerves has been shown to effectively inhibit
detrusor contractions caused by NDO.2–7 This occurs through
modulation of both residual supra-sacral and segmental reflex
pathways during storage and voiding phases of themicturition
cycle.8,9 The neuromodulation can be given continuously, or
conditionally only when NDO occurs.
Continuous neuromodulation has been applied through
surface electrodes on the dorsal penile or clitoral nerves,
percutaneous electrodes on the tibial nerve8–10 and anal11 and
intra-vaginal plug electrodes.12 Implanted electrical stimula-
tion devices (eg, Medtronic Interstim®) have also been used
extensively to provide continuous neuromodulation of the
sacral nerves in the treatment of neurogenic bladder
dysfunction. A systematic review of sacral neuromodulation
has shown that this treatment can be useful in selective
cases.13
By contrast, conditional neuromodulation (CN) is applied
only when NDO occurs using different mechanisms for
detection of detrusor activity.14–21 This has been achieved
through recording of intra-vesical pressure,14,15 by using the
dyssynergic activity of the urethral or anal sphincters16–18 or
with more technical difficulty by recording from bladder
sensory nerves.19 CN has been shown to be as effective as
continuous neuromodulation in suppressing NDO and
increasing bladder capacity but has the additional benefits
of reducing both electrical power consumption and potential
reflex habituation.15 Although CN appears to be a good
alternative to continuous neuromodulation, none of the
previous studies have developed beyond the laboratory into
clinically applicable devices.
We describe a proof of principle study of a novel,
patented,20 wearable, and biocompatible CN device to control
NDO which overcomes some of the disadvantages of
implanted continuous neuromodulation devices.
The conditional anorectal neuromodulation device
(CARM) provides transrectal stimulation to the mixed
pudendal nerves lying in Alcock's canal to suppress NDO.
The stimulation is provided conditionally by simultaneously
recording and utilizing the electromyographic activity of the
co-contraction of the external anal sphincter (EAS) as a
trigger for the neuromodulation (Fig. 1A).
The aim of this study was to determine the efficacy of
neuromodulation delivered through the CARMdevice and the
reliability of using the activity of the dyssynergic anal
sphincter as a marker for NDO in male subjects with SCI.
2 | MATERIALS AND METHODS
The study protocol was approved by an independent Ethics
Committee. The device was manufactured by the Department
of Medical Physics, UCL. The study was conducted at the
London Spinal Cord Injury Centre, Royal National Ortho-
paedic Hospital, Stanmore, UK.
2.1 | Patient selection
Male subjects (age range 18-75 years) with a complete or
incomplete supra-sacral SCI, of at least 24 months duration,
were eligible to take part in the study. Subjects were
excluded if they had any other neurological disorder,
previous surgery to the bladder or sphincters, or previous
intra-detrusor botulinum toxin injections. They were also
excluded if they showed positive leucocytes and nitrites on
urinalysis on the day of investigation. All patients were
requested to stop any anti-muscarinic medication 7 days
prior to investigation.
2.2 | Standard cystometry
Standard filling cystometrograms were performed using
4.5 Ch catheters for measuring bladder pressure (Pves) and
rectal pressure (Pabd); detrusor pressure (Pdet) was
obtained by subtracting Pabd from Pves. Transducers
were zeroed to atmosphere at the start of the investigation
and placed at the level of the symphysis pubis, with patients
in the supine position. The bladder was filled retrogradely
with sterile saline through an additional 10 Fr filling line.
For each cystometrogram maximum cystometric capacity
(MCC), maximum detrusor pressure (MDP) and leakage
were recorded.
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2.3 | Wearable conditional neuromodulation
device
A prototype of the CARM device was developed for
delivering CN (Fig. 1B). The device was controlled through
a computer system with a CED power 1401 analog to digital
converter (ADC), running Spike 2 software (Cambridge
Electronic Design, Cambridge, UK). The stimulation was
delivered from an electrically isolated constant current
stimulator (DS7A, Digitimer, Welwyn Garden City, AL7
3BE, UK). The recording electrodes were connected to a
Lectromed 5361 biopotential amplifier (Digitimer), the input
EMG was AC coupled with a time constant of 0.03s, the
signal was filtered using a digital band pass filter with cut off
frequencies 60-500 Hz, and then full wave rectified and
smoothed with a time constant of 1 s. The customized data
acquisition program enabled real-time recording of cysto-
metric pressures and sphincter EMG recordings. A threshold
trigger for stimulation could be set on either the pressure or
EMG channel.
The CARM device was inserted manually with lubricat-
ing medical gel into the rectum in the correct orientation. The
FIGURE 1 (A) Diagrammatic representation of conditional neuromodulation control in the CARM device. (B) The CARM device was
manufactured from medical grade silicone rubber and shaped for conformity within the anal canal into which the device was inserted with the aid
of electrode gel (a). The electrodes were manufactured using medical grade stainless steel. The EMG recording electrodes were located equi-
distant around the circumference to ensure best contact with the anal sphincter (b). The stimulating electrodes were designed as a bipolar pair
bilaterally and directed toward the trajectory of the pudendal nerves (c) through Alcock's canal located near to the anorectal junction. A reference
electrode was located at an electrically inactive position on the stem of the device
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correct position of the CARM device in situ is shown
(Fig. 1B)
2.4 | Baseline cystometrogram and EMG
threshold determination
With the CARM device in situ, three baseline cystometro-
grams were performed at a filling rate of 60 mL/min in the
supine position. Detrusor pressure and sphincter EMG were
recorded simultaneously (Fig. 2A). The EMG threshold for
each patient was determined by calculating the value of the
processed EMG signal at the time that Pdet exceeded
15 cmH2O (TNDO) for each of the baseline fills. In order to
reduce the incidence of false negatives, the minimum of the
three values was used as the trigger for CN (EMGthreshold.
minimum).
2.5 | Conditional neuromodulation
CN was applied through the integral electrodes on the
CARM, using biphasic balanced pulses. The amplitude of
stimulation was determined for each subject based on twice
sensory threshold or maximum that could be tolerated. A
test fill at 60 mL/min was carried out in each subject to
determine whether a single burst of CN could suppress
NDO and be tolerated. Subjects were excluded from the
study if NDO was not suppressed at maximum tolerated
stimulation amplitude.
The bladder was then re-filled at a physiological rate of
15 mL/min (Fig. 2B) with CN applied through the CARM. A
60-s train of stimulation was triggered each time EMGthres-
hold.minimum was reached. The end point of the experiment
was determined as when CN could no longer suppress NDO, a
volume of 500 mL was reached or there was leakage.
2.6 | Statistical analysis
The Wilcoxon sign rank test was used to compare MCC and
MDP at baseline and during CN.
3 | RESULTS
3.1 | Patient demographics
Twelve male subjects with SCI were recruited into the study.
Following baseline cystometrogram, four were excluded as
they did not demonstrate NDO or their bladder capacity
exceeded 450 mL. Four subjects were classified with ASIA
Impairment Score (AIS) complete (A) and four were
incomplete (B-D). The level of injury, year of injury, AIS,
and bladder management were recorded (Table 1).
FIGURE 2 (A) An example of a typical baseline
cystometrogram in this study showing the subtracted detrusor
pressure (Pdet = Pves-Pabd), the raw EAS EMG, and the processed
EAS EMG activity recorded through anal sphincter electrodes on
the CARM device. Maximum cystometric capacity (MCC) was
defined as the volume at which there was urine leakage, 450 ml
saline was infused, or the subject described discomfort. Maximum
detrusor pressure (MDP) was also recorded. Raw and processed
sphincter EMG recordings were used to determine threshold value
for stimulation. The baseline cystometry was repeated three times
in each subject in order to determine the repeatability of the
parameters recorded. Subjects were excluded from the study if they
did not demonstrate NDO or if the infusion volume exceeded
450 ml. The baseline CMG also shows a typical NDO contraction
with associated DSD seen as an increase in EAS EMG activity.
EMGthreshold was determined from the value of the processed
EMG at the time that Pdet exceeded 15 cmH2O above baseline
value (TNDO). The minimum of the three EMGthreshold values
(EMGthreshold.minimum) was used as the trigger for subsequent
conditional neuromodulation. (B) Typical detrusor pressure trace
showing conditional neuromodulation through CARM device with
multiple triggering of neuromodulation based on the activity in the
anal sphincter. The stimulation parameters were optimized for each
individual subject based on their sensory or motor threshold to
stimulation through the device. For incomplete subjects, the sensory
threshold was determined by the amplitude at which they could
first feel a 5-s burst of stimulation through the device. For
complete subjects, the threshold was determined by the current at
which a motor response (M-wave) was elicited by a 30-s burst of
stimulation. The amplitude of the stimulating current was then set
at twice this threshold. The stimulation frequency was set at 15 pps
and pulse width 200 μs and was applied for periods of 60 s. The
threshold for triggering conditional neuromodulation was set from
the EMGthreshold.minimum value as described above. The number
of stimulation bursts was recorded and for each suppressed NDO
contraction, the peak detrusor pressure was measured. The time
between each consecutive triggered stimulation was also recorded
(Table 2). The MCC and MDP for conditional neuromodulation
cystometrograms were also recorded
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3.2 | Baseline cystometry and sphincter EMG
The results of the baseline cystometry (MCC and MDP) are
shown in Table 1. A corresponding increase in EASEMGwas
observed in each subject who demonstrated NDO, consistent
with the presence of DSD. The EMG threshold.minimum
values are shown in Table 2.
3.3 | Conditional neuromodulation
A typical trace of CN through the CARM device is shown in
Fig. 2B. Two subjects were excluded from the study after the
trial CN; one subject with AIS D could not tolerate the
required level of stimulation to suppress NDO and the second
(AIS A) experienced slight AD symptoms (headache and
flushing) during filling. The stimulation currents and number
of suppressed contractions are shown in Table 2, with a mean
current of 62 ± 16 mA. There was a statistically significant
increase in MCC from a median (interquartile range) value of
153 (88-308) milliliter at baseline to 446 (242-530) milliliter
during CN (Fig. 3A). There was a statistically significant
decrease in MDP from 93 (68-122) cmH2O at baseline to
62 (44-72) cmH2O during CN (Fig. 3B). The mean number of
TABLE 1 Table showing demographic details of the eight patients in the study detailing level of injury, date of injury, ASIA Impairment Score, and
current bladder management
Baseline (mean and
SD of three fills)
Conditional
neuromodulation
Patient
no.
Level of
injury
ASIA
impairment
score
Date
of
injury
Bladder
management
MCC
(mL)
MDP
(cmH2O)
MCC
(mL)
No. of
contractions
suppressed
Mean
peak DP
(cmH2O)
MDP
(cmH2O)
P1 T11-T12 B 2006 ISC+AM 152 ± 3 57 ± 3 195 2 42 56
P2 T10-T11 A 2005 ISC+AM 97 ± 9 86 ± 10 488 3 54 72
P3 C3-C7 D 2002 ISC+AM 155 ± 17 100 ± 9 530 4 68 73
P4 T4 A 2007 IC+AM 80 ± 25 106 ± 19 510 7 51 69
P5 T12 D 1998 ISC+pads 231 ± 50 138 ± 35 289 3 34 41
P9a C6-C7 D 2000 ISC+AM 241 ± 25 57 ± 7
P11 T3-T4 A 2001 ISC 386 ± 28 79 ± 4 405 4 45 48
P12a T2 A 1987 ISC+AM 429 ± 83 79 ± 15
ISC, intermittent self-catheterization; AM, anti-muscarinic medication; IC, indwelling catheter. Mean baseline cystometric data from eight patients entered into the study.
Cystometric data (MCC and MDP) for six patients who underwent conditional neuromodulation through CARM device.
aPatients excluded from study during conditional neuromodulation. P9 did not show successful suppression of NDO which may have been due to insufficient stimulation
current, as he was unable to tolerate higher than 25 mA. P12 experienced autonomic dysreflexic symptoms so was excluded from further study.
TABLE 2 Table showing mean EMGthreshold values for three baseline cystometrograms and EMGthreshold.minimum value used for subsequent
conditional neuromodulation fill
Negative Positive
Patient
no.
Mean EMG at
Pdet = 15 cmH2O (μV)
EMG
threshold min
(μV)
Stimulation
threshold
(mA)
Stimulation
current
(mA) True False True False
Unwanted
stimulation
% PPV
P1 8 ± 4 5.2 30 57 – – 2 – – 1.0
P2 3 ± 1 2.3 30 60 – – 9 – – 1.0
P3 11 ± 4 8.3 30 60 – – 13 5 14 0.7
P4 5 ± 3 3.5 30 60 – – 16 2 6 0.9
P5 35 ± 2 32.4 3 40 – – 6 4 22 0.6
P9 31 ± 5 25.4 20 25
P11 6 ± 2 4.6 50 90 – – 6 3 15 0.7
P12 10 ± 2 8.1 40 80
The stimulation threshold (motor or sensory) and the actual stimulation current is also shown. The number of true and false positive and negative stimulations for the
conditional neuromodulation fill are also shown with the number of % of unwanted stimulation and the positive predictive indicator (PPV).
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suppressed detrusor contractions was 4 ± 2. The time interval
between detrusor contractions became shorter as the
bladder capacity increased, until the neuromodulation could
no longer suppress them. The time intervals were fitted with a
one-phase exponential decay curve which had a half-life of
0.49 (Fig. 4).
3.4 | Positive predictive value for EAS EMG
activity
During the CN fills, using the EMGthreshold.minimum to
trigger stimulation, false positive and false negative detec-
tions were calculated for each patient (Table 2). There were
no false negative detections during the CN fills. The average
number of true positives throughout the CN fills was 9 (±5)
and the average number of false positives was 2 (±2). The
mean positive predictive value (PPV) for the series of fills
was 0.8 (±0.2) for the six patients.
4 | DISCUSSION
This investigation was a proof of principle study of a novel
wearable device to control NDO in male subjects with SCI
using CN. The CARM device, worn in the ano-rectum
delivers neuromodulation to the pudendal nerves lying in
Alcock's canal. The neuromodulation was delivered
FIGURE 3 (A) Box and whisker graph representing the median (and interquartile range) of maximum cystometric capacity (MCC) during
baseline and conditional neuromodulation fills for six subjects. Error bars denote range. The graph to the left shows the individual values for
MCC at baseline and during conditional neuromodulation. The * indicates a P value <0.03 following a Wilcoxon sign rank test. (B) Box and
whisker graph representing the median (and interquartile range) of maximum detrusor pressure (MDP) during baseline and conditional
neuromodulation fills for six subjects. Error bars denote range. The * indicates a P value <0.03 following a Wilcoxon sign rank test. The graph
to the left shows the individual values for MDP at baseline and during conditional neuromodulation
FIGURE 4 The mean time between each consecutive detrusor
contraction for six subjects during conditional neuromodulation. The
regression line shows a one-phase exponential decay with a time
constant of 0.49 and r2 of 0.98
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conditionally, in response to simultaneously measured EMG
activity in the EAS. The EMG EAS activity corresponded
well with NDO. The results of this pilot study in six SCI
subjects with NDO showed that CN through the CARM
device statistically significantly increased MCC and signifi-
cantly reduced MDP. This study has shown for the first time
that CN can be delivered and triggered through a single device
worn in the anal canal.
The device and procedure were well tolerated in the
majority of the subjects; one subject with an incomplete lesion
could not tolerate the stimulation through the device required
to suppress NDO.
Neuromodulation has been used in many previous studies
to suppress NDO in patients with supra-sacral SCI.2–17 using
a variety of different electrode sites. Typical stimulation
parameters which give effective detrusor inhibition have been
well documented.14 Optimal frequency ranges are given as 5–
50 Hz. Very low frequencies can be associated with
unpleasant sensations, so 10–15 pps are normally used.
Balanced biphasic pulses with pulse width 200–500 μs are
commonly used to minimize electrochemical reactions at the
electrode-tissue interface. The amplitude of stimulation must
be sufficient to elicit activity in the relevant nerves, but not so
high as to cause painful sensations. The stimulation amplitude
is therefore normally determined for each individual patient
with a minimum level of twice the motor threshold for the
pudendo-anal reflex in complete patients.14 In the current
study, a stimulation frequency of 15pps and pulse width of
200 μs was used. The range of stimulation currents was
between 40 and 90 mA with a mean of 61.16 mA, the
incomplete subjects had lower stimulation currents than the
complete subjects reflecting the lower sensory thresholds.
Only one subject (iSCI) could not tolerate stimulation current
high enough to suppress NDO. Therefore the parameters
required when stimulating the pudendal nerves lying in
Alcock's canal are similar to those used in surface stimulation
of the dorsal penile/clitoral nerve, and were well tolerated
even in the incomplete patients. A direct comparison with the
currents used through implanted devices such as the
Medtronic Interstim is not possible as the settings are not
easily determined and success in SCI patients is limited.
CN has previously been described using detrusor pressure
as a trigger for stimulation.14–16 Although CN has been shown
to be as effective as continuous neuromodulation in increasing
bladder volume and reducing detrusor pressure, it has only to
date been carried out under laboratory conditions, as long-term
remote pressure measurement within the bladder is not
possible. Fjorback et al21 described a portable device which
was based around ambulatory urodynamics and DPN stimula-
tion which demonstrated that CN was effective at increasing
bladder capacity by suppressing NDO in patients with SCI in a
more physiological setting than repeated laboratory fills.
However, this technique could still only be used as a screening
tool rather than a treatment in itself, until a non-invasive
technique for measuring bladder pressure is developed.
Therefore, an alternative to detrusor pressure as a trigger
for CN was required. Blaivas et al1 have described the
relationship between the external urethral sphincter (EUS)
and detrusor activity following SCI. They described three
types of DSD, in which the EUS co-contracts with the
detrusor muscle during NDO contractions. The dyssynergic
sphincter contractions are supplied by the pudendal nerve
which innervates the skeletal muscles in the pelvic area; it has
been shown in cats and humans that the EAS also contracts
during dyssynergic contractions of the EUS.22–23 Three
potential signals are therefore available as a trigger for
detecting onset on NDO; pudendal nerve activity (ENG),
EUS EMG and EAS EMG. Wenzel et al22 have described the
use of pudendal nerve ENG in the spinalized cat model to
trigger CN to suppress NDO contractions successfully but the
technique has not yet been translated to a device for use in
humans. The EUS EMG is only recordable using needle
electrodes which are invasive and can be uncomfortable as
well as not being practical for long-term monitoring. By
contrast, the EAS EMG can be readily recorded from an
electrode placed in the anal canal as described in the current
study.
The use of the dyssynergic activity of theEASduringNDO
contractions has been speculated by previous authors. Horvath
et al16 used EAS EMG to trigger dorsal penile nerve
stimulation and showed similar increases in bladder capacity
with both conditional and continuous stimulation, but with
much reduced stimulation times when using CN. They
reported that there were no false negative detections of
NDO. Wenzel et al17 describe a retrospective study of
urodynamic traces of 47 patients and prospective study of
79 patients of which 81 had SCI, which showed that signal
processed EAS EMG could be a reliable indicator of NDO
contraction.They also used a closed loop systemusing theEAS
as a trigger for CN using dorsal penile nerve stimulation in the
cat model which successfully detected and suppressed NDO
contractions. Both authors report that there may be some false
positive stimulation which would create an open loop rather
than closed loop system but that false positives are better than
false negatives. Indeed, in our study, we have shown that there
were no false negative stimulations and a mean positive
predictive value (PPV) for the series of fills was 0.81 (±0.17)
for the six subjects. The incidence of false positives may
increase when the device is used on a day-to-day basis due to
artifacts in the EAS EMG or reflex activity of the sphincter.
Enhanced EMG signal processing and better optimization of
individual thresholds may decrease the incidence of false
positives.
Using the wearable device, we have described significant
increases in bladder capacity during CN triggered by EAS
EMG activity. Median (interquartile range) baseline bladder
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capacity in the six patients was 153 (88-308) milliliter which
increased to 446 (242-530) milliliter following CN represent-
ing a more than a twofold increase in bladder capacity. These
results are consistent with the findings of Kirkham et al14 and
Dalmose et al15 who also used slow filling rates but used
bladder pressure to trigger CN. The MDP during the CN was
also significantly reduced when compared to control fills and
therefore would provide protection of the upper tracts. Sub-
group analysis between subjects with complete and incom-
plete SCI was not possible due to the small sample size, but of
the six subjects who were analyzed, three were AIS A and
three were AIS B-D.
During CN, the time between each successive NDO
contraction was recorded until the neuromodulation could no
longer effectively suppress the contractions. The time between
each contraction was observed to decrease as the bladder
volume increased following a one-phase exponential decay
with a half-life of 0.49. This decrease in time between
consecutive contractions has also been noted by other
researchers using CN17 and it has also been shown in the
spinal cat that the frequency of unstable contractions increases
with bladder volume.24 The decay in time between successive
contractions could be used to notify the patient when their
maximum bladder capacity is approached, allowing them to
empty their bladder before any leakage occurred.
4.1 | Study limitations and outlook
As this was a proof of principle study, it is recognized that one
of its limitations was the small number of subjects tested. In
addition, of the eight subjects undergoing neuromodulation,
two could not tolerate the stimulation through the device and
were withdrawn before the final part of the study. One subject
with an incomplete injury could not tolerate the required
strength of stimulation and one developed symptoms of
autonomic dysreflexia following stimulation. This may limit
the device use in some patients, but careful pre-assessment
would identify these patients as with other neuromodulation
devices. We are currently redesigning the device to improve
electrode design25 and seeking a manufacturer to develop it
further and carry out longer term safety, efficacy, and
tolerability trials in a larger population group. We believe this
device could offer an alternative to implantable neuro-
modulation devices in some patients, and may eventually
benefit patients with other neurological and non-neurological
detrusor overactivity
5 | CONCLUSIONS
It has been shown for the first time that CN can be delivered
and triggered via a single device placed in the anal canal. The
pudendal nerves lying in Alcock's canal were stimulated
through thewall of the anal canal, and the dyssynergic activity
of the EAS was used to detect NDO and trigger neuro-
modulation. Significant increases in bladder capacity and
decreases in maximum detrusor pressure were demonstrated
in a group of six male spinal cord injured subjects.
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